{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:57:31Z","timestamp":1740135451824,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["17411968500"],"award-info":[{"award-number":["17411968500"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai","award":["PWZxq2017-05"],"award-info":[{"award-number":["PWZxq2017-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12872-018-0853-x","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T09:06:22Z","timestamp":1529312782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Chaoyue","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-6964","authenticated-orcid":false,"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/hrt.2008.160457","volume":"95","author":"A Sch\u00f6mig","year":"2009","unstructured":"Sch\u00f6mig A, Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how? Heart. 2009;95:1280\u20135.","journal-title":"Heart"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155\u201379.","journal-title":"Eur Heart J"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/clc.20884","volume":"34","author":"XD Wang","year":"2011","unstructured":"Wang XD, Zhang DF, Zhuang SW, Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol. 2011;34:332\u20138.","journal-title":"Clin Cardiol"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1161\/STROKEAHA.112.665331","volume":"43","author":"WN Whiteley","year":"2012","unstructured":"Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904\u20139.","journal-title":"Stroke"},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Circulation. 2012;126:2020\u201335.","journal-title":"Circulation"},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"853_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","volume":"11","author":"AK Rao","year":"1988","unstructured":"Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL. Thrombolysis in myocardial infarction (TIMI) trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1\u201311.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR9","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541\u2013619.","journal-title":"Eur Heart J"},{"key":"853_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","volume":"5","author":"L Bonello","year":"2007","unstructured":"Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630\u20136.","journal-title":"J Thromb Haemost"},{"key":"853_CR11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","volume":"129","author":"M Lamberts","year":"2014","unstructured":"Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129:1577\u201385.","journal-title":"Circulation"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","volume":"28","author":"PP Karjalainen","year":"2007","unstructured":"Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726\u201332.","journal-title":"Eur Heart J"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacc.2007.11.035","volume":"51","author":"JM Ruiz-Nodar","year":"2008","unstructured":"Ruiz-Nodar JM, Mar\u00edn F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818\u201325.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.amjcard.2009.03.053","volume":"104","author":"M Gilard","year":"2009","unstructured":"Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol. 2009;104:338\u201342.","journal-title":"Am J Cardiol"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.amjcard.2015.03.033","volume":"116","author":"MG Mennuni","year":"2015","unstructured":"Mennuni MG, HalperinJL BS, Schoos MM, Theodoropoulos KN, Meelu OA, et al. Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR registry). Am J Cardiol. 2015;116:37\u201342.","journal-title":"Am J Cardiol"},{"key":"853_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1253\/circj.CJ-15-0923","volume":"80","author":"A Sambola","year":"2016","unstructured":"Sambola A, Mutuberr\u00eda M, Garc\u00eda Del Blanco B, Alonso A, Barrab\u00e9s JA, Alfonso F, et al. Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification. Circ J. 2016;80:354\u201362.","journal-title":"Circ J"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","volume":"65","author":"KA Fiedler","year":"2015","unstructured":"Fiedler KA, Maeng M, Mehilli J, Schulz-Sch\u00fcpke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65:1619\u201329.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jcin.2016.04.027","volume":"9","author":"KC Koskinas","year":"2016","unstructured":"Koskinas KC, R\u00e4ber L, Zanchin T, Pilgrim T, Stortecky S, Hunziker L, et al. Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;9:1473\u201383.","journal-title":"JACC Cardiovasc Interv."},{"key":"853_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1253\/circj.CJ-09-0880","volume":"74","author":"F Gao","year":"2010","unstructured":"Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J. 2010;74:701\u20138.","journal-title":"Circ J"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s00380-013-0399-x","volume":"29","author":"SY Suh","year":"2014","unstructured":"Suh SY, Kang WC, Oh PC, Choi H, Moon CI, Lee K, et al. Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessel. 2014;29:578\u201383.","journal-title":"Heart Vessel"},{"key":"853_CR21","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354\u201362.","journal-title":"N Engl J Med"},{"key":"853_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejim.2011.07.016","volume":"23","author":"XD Wang","year":"2012","unstructured":"Wang XD, Zhang DF, Liu XB, Lai Y, Qi WG, Luo Y, et al. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Intern Med. 2012;23:48\u201353.","journal-title":"Eur J Intern Med"},{"key":"853_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","volume":"108","author":"P Fontana","year":"2003","unstructured":"Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108:989\u201395.","journal-title":"Circulation"},{"key":"853_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12265-017-9774-9","volume":"11","author":"T Strisciuglio","year":"2018","unstructured":"Strisciuglio T, Barbato E, De Biase C, Di Gioia G, Cotugno M, Stanzione R, et al. T2238C atrial natriuretic peptide gene variant and the response to antiplatelet therapy in stable ischemic heart disease patients. J Cardiovasc Transl Res. 2018;11:36\u201341.","journal-title":"J Cardiovasc Transl Res"},{"key":"853_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000488101","volume":"140","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhu J, Li H, Wang L, Niu J, Zhu B, et al. Study of the association of PEAR1, P2Y12, and UGT2A1 polymorphisms with platelet reactivity in response to dual antiplatelet therapy in Chinese patients. Cardiology. 2018;140:21\u20139.","journal-title":"Cardiology"},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, GRAVITAS Investigators, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097\u2013105.","journal-title":"JAMA"},{"key":"853_CR28","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet JP, Cuisset T, Rang\u00e9 G, Cayla G, Elhadad S, Pouillot C, et al. ARCTIC investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100\u20139.","journal-title":"N Engl J Med"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"D Trenk","year":"2012","unstructured":"Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, M\u00fcller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on Clopidogrel to guide alternative therapy with Prasugrel) study. J Am Coll Cardiol. 2012;59:2159\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","volume":"388","author":"G Cayla","year":"2016","unstructured":"Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al. ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388:2015\u201322.","journal-title":"Lancet"},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903\u201312.","journal-title":"Lancet"},{"key":"853_CR32","first-page":"277","volume":"5","author":"D Zahger","year":"2009","unstructured":"Zahger D, Ilia R. Coronary stenting in warfarin treated patients. Euro Intervention. 2009;5:277\u201381.","journal-title":"Euro Intervention"},{"key":"853_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2009.03.044","volume":"54","author":"DR Holmes Jr","year":"2009","unstructured":"Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54:95\u2013109.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1160\/TH09-08-0580","volume":"103","author":"GY Lip","year":"2010","unstructured":"Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/ stenting. Thromb Haemost. 2010;103:13\u201328.","journal-title":"Thromb Haemost"},{"key":"853_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.ahj.2006.06.024","volume":"152","author":"GC Flaker","year":"2006","unstructured":"Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152:967\u201373.","journal-title":"Am Heart J"},{"key":"853_CR36","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107\u201315.","journal-title":"Lancet"},{"key":"853_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","volume":"31","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J. 2010;31:1205\u201311.","journal-title":"Eur Heart J"},{"key":"853_CR38","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"853_CR39","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","volume":"8","author":"LR Jackson 2nd","year":"2015","unstructured":"Jackson LR 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv. 2015;8:1880\u20139.","journal-title":"JACC Cardiovasc Interv"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, GYH L, Ellis SG, Kimura T, et al. RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"853_CR41","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0853-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-018-0853-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0853-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T19:06:53Z","timestamp":1560798413000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-018-0853-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1186\/s12872-018-0853-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were performed in accordance with rules of the Ethical Committee of Shanghai East Hospital, Tongji University on human clinical trials and in accordance with the Helsinki Declaration revised in 2008. This study was approved by the Medical Ethics Committee of Shanghai East Hospital, Tongji University School of Medicine. Informed written consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"120"}}